Drug Trial Radar · NCT00619710
Complicated Skin and Skin Structure Infections
Last checked: Nov 19, 2026Latest source record: Sep 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Planned (sponsor's estimate)
Start
Feb 2001
Primary completion
Dec 2003
Study completion Apr 2004
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
Conditions
- Skin Infection
- Abscess
- Cellulitis
Interventions
MeropenemDrug
Intravenous
Imipenem-cilastatinDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary measure is clinical response after all antibacterial treatment is stopped).Time frame: 7-28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.